Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT — Stella

Home/Hepatocellular Carcinoma (HCC)/Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

View on ClinicalTrials.gov

Recruiting

Back to Hepatocellular Carcinoma (HCC) trials

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

West China Hospital, Chengdu, Sichuan

Key details

Phase

Safety & dosing

Sponsor

West China Hospital

Enrollment target

~33 participants

Started

October 2024

Primary completion

October 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.